Clinical Trials
59 trialsEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
TNTIT
Fudan University
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Washington University School of Medicine
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
M.D. Anderson Cancer Center
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
University of Iowa
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
R-IMMUNE
Grand Hôpital de Charleroi
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Mansoura University
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Case Comprehensive Cancer Center
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
M.D. Anderson Cancer Center
BAH248
Essen Biotech
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
West China Hospital
MIRCA & MIPAC
Radboud University Medical Center
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Shanghai Minimally Invasive Surgery Center
Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Online Adaptive Radiation Therapy for Rectal Cancer
Peking Union Medical College Hospital
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
Universitätsklinikum Hamburg-Eppendorf
Study to Nivolumab Following Preoperative Chemoradiotherapy
National Cancer Center Hospital East
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer
Imperial College London
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
UNC Lineberger Comprehensive Cancer Center
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
University of Texas Southwestern Medical Center
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Jonsson Comprehensive Cancer Center
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
Validation of ICG to Identify the Urethra During Rectal Surgery
Oxford University Hospitals NHS Trust
Fluorescence Targeted Pelvic Lymph Node Mapping
Oxford University Hospitals NHS Trust
Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
Swiss Cancer Institute
External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer
Swiss Cancer Institute
Genistein in Treatment of Metastatic Colorectal Cancer
Icahn School of Medicine at Mount Sinai
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
City of Hope Medical Center
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
Maastricht Radiation Oncology
Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer
Medical University of South Carolina
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
Stanford University
EXCITE
University College, London
HyRec
University of Erlangen-Nürnberg Medical School
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Massachusetts General Hospital
High Dose Vitamin D Study
University of British Columbia
The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer
Sun Yat-sen University
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
Roswell Park Cancer Institute
Hydralazine as a Demethylating Agent in Rectal Cancer
University of Arkansas
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
University of Chicago
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
Roswell Park Cancer Institute
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
Roswell Park Cancer Institute